Breaking Finance News

A statement released earlier today by B. Riley about VALERITAS HOLDINGS COM (NASDAQ:VLRX) ups the target price to $7.50

In a report issued 09/26/2016 B. Riley bumped up the target of VALERITAS HOLDINGS COM (NASDAQ:VLRX) to $7.50 reporting a potential upside of 0%.

Boasting a price of $0.00, VALERITAS HOLDINGS COM (NASDAQ:VLRX) traded 4.17% higher on the day. With the last close down 10.11% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. VALERITAS HOLDINGS COM has recorded a 50-day average of $5.53 and a two hundred day average of $5.68. Volume of trade was up over the average, with 2,560 shares of VLRX changing hands over the typical 498

Performance Chart

VALERITAS HOLDINGS COM (NASDAQ:VLRX)

With a total market value of $0, VALERITAS HOLDINGS COM has 52 week low of $5.00 and a 52 week high of $6.50 .

Brief Synopsis On VALERITAS HOLDINGS COM (NASDAQ:VLRX)

Valeritas, Inc. is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company's portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin. Its development portfolio also includes the h-Patch technology, the Mini-Ject pre-filled needle-free delivery system and the Micro-Trans microneedle transdermal delivery patch. Its h-Patch is a controlled delivery technology platform designed to deliver drugs into subcutaneous tissue. The Mini-Ject represents needle-free injection system, combining a range of fully disposable pre-filled options. Micro-Trans microneedle array patch technology enables drug delivery into the dermis without limitations of drug size, structure, charge or the patient's skin characteristics.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *